Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
The latest World Gold Council Gold Demand Trends report, which covers the period July-September 2013, highlights the resilience of the global gold market in what is traditionally a slower quarter for gold demand. The continued growth in consumer demand across the globe and the strength of Asian gold demand overall, reinforces the patterns first seen at the beginning of 2013, clear evidence of the self-balancing nature of the global market.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/60364-world-gold-council-gold-journey-west-east-markets-balance-invest-outflows
EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today that new 10 year data from an international registry-based multi-center study shows 83 percent of patients had no biopsy evidence of disease after treatment with Ablatherm® HIFU, supporting the technology as a standard primary treatment for localized prostate cancer. Study results were presented at the American Urological Association (AUA) 2011 Annual Meeting, Washington, D.C.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/edap/49862/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
The duty free and travel retail community assembled last month for the most important event in the industry’s history in the Asia Pacific region. TFWA Asia Pacific & GATE ONE2ONE, the annual conference and exhibition event in Singapore for stakeholders in the industry in the dynamic Asia Pacific region, was larger and better attended than at any time in its 17 year history, evidence of the growth potential of the trade in the dynamic Asia Pacific region.
Revenue from the global duty free and travel retail industry, and other non-aeronautical revenue streams such as advertising, food & beverage and car parking, is of immense importance to airports and to airlines. It not only provides vital funds for the maintenance and development of the airport facilities, its contribution to an airport’s coffers means that airport charges can be held down for airlines and consequently passenger fares can be kept down. It is estimated that 50% of an international airport’s revenue is derived from duty free, travel retail and other non-aviation activity. At Paris Charles de Gaulle airport, for example, commercial activities generate 60% of total revenues for the airport.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53836-tfwa
Research led by the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project has identified a fusion gene responsible for almost 30 percent of a rare subtype of childhood leukemia with an extremely poor prognosis.
The finding offers the first evidence of a mistake that gives rise to a significant percentage of acute megakaryoblastic leukemia (AMKL) cases in children. AMKL accounts for about 10 percent of pediatric acute myeloid leukemia (AML). The discovery paves the way for desperately needed treatment advances.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58586-st-jude-children-s-research-hospital-gene-sequencing-childhood-leukemia
Early findings from a major research initiative of the Crohn’s & Colitis Foundation of America (CCFA) suggest that specific bacteria play a central role in Crohn’s disease and ulcerative colitis (UC), also known as inflammatory bowel diseases (IBD). The evidence raises the possibility of developing new treatments to target the gut microbiome—the “ecosystem” of microbes populating the intestines—linked to the development of IBD.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7204351-crohn-s-colitis-foundation-of-america-gut-bacteria-new-strategies-to-prevent/
Ramon Munoz has been falsely convicted of murder. Desperate, his family turns to PI Paige Holden. When Paige witnesses Ramon’s wife executed , the woman having handed Paige evidence that will prove his innocence, she is thrown into a case which places her job, friends and life in jeopardy. Learn about the book here http://bit.ly/vYuUEL Learn about the author here http://bit.ly/KarenRose Thriller
Citing new evidence that many parents lack the information to prevent obesity in their children, Shape Up America! and National Turkey Federation (NTF) today announced a national mobilization to help First Lady Michelle Obama fight childhood obesity by arming parents with the facts and tools to make simple changes – or “upgrades” – in favorite meals and physical activity levels so everyone can reap the benefits of taking in less calories.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/shapeup/49869/
On the eve of World Cancer Day 2015, amidst the ongoing cost-of-cancer-care debate, PACE (Patient Access to Cancer care Excellence), a Lilly Oncology initiative, is launching the PACE Continuous Innovation Indicators™ (CII). CII is the first evidence-based, customizable online tool to review progress against cancer over time—initially covering 12 cancer types. The purpose of the tool is to inform public policy reforms and other efforts to accelerate continuous innovation against cancer.
“We have seen tremendous progress in cancer treatment and care during the past decades, and continuous innovation, with one discovery building on another, is responsible for most of it,” said John C. Lechleiter, Ph.D., Chairman, President, and Chief Executive Officer of Eli Lilly and Company (NYSE:LLY). “To keep the momentum going, we need policies that support continuous innovation, but first we need a deeper understanding of the innovations that have occurred, and where we need to be.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7419451-eli-lilly-oncology-pace/
Fifteen of 17 booster seats introduced in 2012 earn the top rating of BEST BET from the Insurance Institute for Highway Safety, evidence that more than ever, manufacturers are designing seats to provide good safety belt fit for booster-age children.
The improvements mean that BEST BET boosters now outnumber seats in any of the three other categories for the first time since the Institute released its inaugural booster ratings in 2008. Boosters are supposed to improve how adult lap and shoulder belts fit children so the belts can properly restrain them in crashes. BEST BET boosters correctly position belts on a typical 4-to-8-year-old child in almost any car, minivan or SUV.
A new online resource is now available to help people recognize and find high quality care for alcohol use disorder, which affects more than 15 million adults in the United States. The Alcohol Treatment Navigator, designed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health, is a comprehensive, yet easy-to-use tool to help individuals and their loved ones navigate the often-complicated process of choosing treatment for alcohol problems. With many treatment options available, the navigator makes the search easier by telling them what they need to know - and what they need to do – to find appropriate, quality care.
“We developed this tool to help address the alcohol ‘treatment gap,’” said NIAAA Director George F. Koob, Ph.D. “In any given year, less than 10 percent of individuals diagnosed with alcohol use disorder receive treatment, and many of them do not receive the type of care that best fits their needs. A big reason for that, we believe, is that people with alcohol use disorder often don’t know where to turn for help. The Alcohol Treatment Navigator offers a comprehensive strategy to help people search for professionally-led, evidence-based alcohol treatment, which should improve their chances for success.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8179051-niaaa-alcohol-treatment-navigator/
